Dec. 30 at 3:28 PM
$CELZ Ouch--hopefully yesterday's drop was the result of year-end selling pressure and not a precursor to disappointing trial data. Either way, it makes the extended quiet more challenging.
Per recent 10-Q and 8-K, CELZ had 3,696,668 OS after the exercise of 1,116,136 warrants at
$3.75 with
$10.0–10.5M in cash available at end of November 2025 (after the October warrant exercise)
Once the 2,790,340 inducement warrants are approved and hit the books at
$2.86 CELZ will add ~
$8.0M in cash and total shares outstanding would rise to ~6.49 million.
That would equal
$18.0M–
$18.5M in cash with a ~6.49M share count and no debt. That suggests about
$2.80 in book value , which means CELZ is currently trading approximately 30% + BELOW book value (how common is that for debt-free, clinical-stage biotech?) (Please correct my math if I am off.)
Nothing, of course, matters more than upcoming trial data, but I am still buying what I can.
